Merck Expands ADC Manufacturing with €70M Investment

Merck recently announced a €70 million expansion at its St. Louis facility, tripling the capacity for Antibody-Drug Conjugate (ADC) manufacturing. This significant investment is aimed at enhancing the company’s CDMO (Contract Development and Manufacturing Organization) capabilities, particularly for early-stage and commercial ADC bioconjugates. New additions include advanced labs, a specialized manufacturing buffer area, and a cold-storage facility.

This expansion aligns with Merck’s commitment to accelerating oncology advancements. By increasing its production capabilities, Merck aims to support clients in advancing ADC therapies that target diseased cells more precisely, thus reducing collateral damage to healthy tissues. Alongside capacity enhancements, Merck has launched specialized tools, such as the Mobius® ADC Reactor and ChetoSensar® technology, which optimize ADC production and address solubility challenges, contributing to faster time-to-market.

Beyond oncology, Merck’s advancements indicate potential applications of ADCs in treating autoimmune, infectious, and neurodegenerative diseases. The expanding therapeutic uses underscore the transformative potential of ADCs and other bioconjugates in delivering targeted therapies, which could provide personalized treatments across multiple conditions.